{"id":9565,"date":"2018-06-19T11:05:21","date_gmt":"2018-06-19T09:05:21","guid":{"rendered":"https:\/\/www.satt.fr\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/"},"modified":"2018-06-19T11:42:44","modified_gmt":"2018-06-19T09:42:44","slug":"theranostique-oncologie-defi-ambitieux-de-startup-oncofactory","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/","title":{"rendered":"Pulsalys : La th\u00e9ranostique en oncologie, le d\u00e9fi ambitieux de la startup OncoFactory"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.pulsalys.fr\/wp-content\/uploads\/2017\/04\/180615_Pulsalys-ZOOM-sur-ONCOFACTORY-1.pdf\" target=\"_blank\" rel=\"noopener noreferrer\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-9623 alignright\" src=\"https:\/\/www.pulsalys.fr\/wp-content\/uploads\/2018\/03\/Ic\u00f4ne-PDF-\u00e0-t\u00e9l\u00e9charger-250x250.jpeg\" alt=\"\" width=\"86\" height=\"86\" \/><\/a>D\u00e9fi relev\u00e9 par la startup de biotechnologies lyonnaise OncoFactory: cr\u00e9er des r\u00e9pliques miniatures de cancer dans un embryon aviaire afin de tester l\u2019efficacit\u00e9 de drogues anticanc\u00e9reuses.<\/strong><\/p>\n<p style=\"text-align: center;\"><iframe loading=\"lazy\" src=\"\/\/www.youtube.com\/embed\/xa14A6Ps1Tk\" width=\"560\" height=\"314\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/p>\n<p style=\"text-align: center;\"><span style=\"color: #333399; font-size: 20px;\"><strong><a style=\"color: #333399;\" href=\"https:\/\/www.pulsalys.fr\/success-story-oncofactory-3-questions-a-frederic-berget-ceo-de-societe\/\" target=\"_blank\" rel=\"noopener noreferrer\">Lire l&#8217;interview de Fr\u00e9d\u00e9ric Berget, CEO de OncoFactory<\/a><\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><strong><span style=\"color: #ff6600;\">Un projet n\u00e9 au c\u0153ur d\u2019un laboratoire acad\u00e9mique<\/span> <\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-9506 size-medium alignright\" src=\"https:\/\/www.pulsalys.fr\/wp-content\/uploads\/2017\/04\/C\u00e9line-DELLOYE-BOURGEOIS-Fr\u00e9d\u00e9ric-BERGET-ONCOFACTORY-7-1-250x174.jpg\" alt=\"\" width=\"250\" height=\"174\" \/><\/p>\n<p style=\"text-align: justify;\">C\u2019est initialement au sein du Centre de G\u00e9n\u00e9tique et de Physiologie Mol\u00e9culaire et Cellulaire (CGPhyMC) que l\u2019id\u00e9e de cr\u00e9er une startup a germ\u00e9 dans l\u2019esprit des deux chercheuses co-fondatrices Val\u00e9rie Castellani-Lincontang et C\u00e9line Delloye-Bourgeois. \u00a0Aujourd\u2019hui h\u00e9berg\u00e9e dans <a href=\"https:\/\/www.labex-cortex.com\/fr\/content\/cgphimc-centre-de-genetique-et-de-physiologie-moleculaire-et-cellulaire\">l\u2019Institut NeuroMyoG\u00e8ne (INMG)<\/a><strong> &#8211; <\/strong>qui est un centre de recherche fondamentale et translationnelle focalis\u00e9 sur le syst\u00e8me neuromusculaire comptant environs 150 personnes-, <strong>OncoFactory<\/strong> d\u00e9veloppe une plateforme qui permet de cr\u00e9er des r\u00e9pliques miniaturis\u00e9es de tumeurs de patient \u00e0 partir d\u2019une biopsie de ce dernier. \u00a0La technologie d\u00e9velopp\u00e9e depuis 2013 consiste \u00e0 transf\u00e9rer des cellules humaines tumorales dans des embryons de poulet pour suivre leur d\u00e9veloppement. <em>\u00ab\u00a0On cr\u00e9e alors un \u00e9quivalent de la tumeur du patient dans un embryon aviaire\u00a0\u00bb<\/em> explique C\u00e9line Delloye-Bourgeois, pr\u00e9cisant que l\u2019id\u00e9e est de \u00ab\u00a0sortir\u00a0\u00bb la tumeur du patient et de la r\u00e9pliquer dans un syst\u00e8me qui va permettre de l\u2019\u00e9tudier.<\/p>\n<p style=\"text-align: right;\"><em><span style=\"color: #333399;\">Fr\u00e9d\u00e9ric Berget (CEO) &amp; C\u00e9line Delloye-Bourgeois(chercheuse), ONCOFACTORY &#8211; Challenge Startups Pulsalys 12\/12\/2017 \u00a9PULSALYS\/NM<\/span><\/em><\/p>\n<p><span style=\"color: #ff6600;\"><strong>Une r\u00e9plique de la tumeur fid\u00e8le \u00e0 la pathologie du patient<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-10105 \" src=\"https:\/\/www.pulsalys.fr\/wp-content\/uploads\/2017\/04\/Embryon-Oncofactory-250x250.jpg\" alt=\"\" width=\"131\" height=\"131\" \/><\/p>\n<p style=\"text-align: justify;\">La r\u00e9plique de tumeur obtenue ici reproduit de fa\u00e7on fid\u00e8le les caract\u00e9ristiques de la maladie du patient, comme, par exemple, sa capacit\u00e9 \u00e0 m\u00e9tastaser. <em>\u00ab\u00a0Nous avons choisi de travailler sur l\u2019embryon de poulet qui est un organisme immature, car c\u2019est aussi un organisme propice \u00e0 la pousse tumorale\u00a0\u00bb<\/em> rappelle la chercheuse. Or dans un embryon (aviaire ou autre), en appliquant les connaissances de la biologie du d\u00e9veloppement (embryologie) \u00e0 la canc\u00e9rologie, il est possible de r\u00e9pliquer (et d\u00e8s lors mod\u00e9liser) des tumeurs dans des tissus pr\u00e9cis. <em>\u00ab\u00a0La tumeur mim\u00e9e peut alors &#8211; comme l\u2019embryon entier- \u00eatre analys\u00e9e dans les 3 dimensions \u00e0 la lumi\u00e8re de la connaissance des structures embryonnaires\u00a0\u00bb<\/em> indique-t-elle. Parmi ses avantages concurrentiels de poids\u00a0: le fait de ne n\u00e9cessiter que de petits \u00e9chantillons (quelques centaines de cellules) et la rapidit\u00e9 de mod\u00e9lisation des tumeurs sur mod\u00e8le animal embryonnaire. La tumeur d\u2019un patient pourrait ainsi \u00eatre r\u00e9pliqu\u00e9e dans une s\u00e9rie d\u2019\u0153ufs recevant diff\u00e9rents sch\u00e9mas de traitements, afin de d\u00e9finir, par exemple le plus efficace pour le patient.<\/p>\n<p style=\"text-align: justify;\"><span style=\"color: #ff6600;\"><strong>Des applications diverses<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\">Plusieurs applications s\u2019ouvrent \u00e0 OncoFactory\u00a0parmi lesquelles :<\/p>\n<ul>\n<li style=\"text-align: justify;\">Tester l\u2019efficacit\u00e9 de drogues anticanc\u00e9reuses candidates<\/li>\n<li style=\"text-align: justify;\">G\u00e9n\u00e9rer des outils d\u2019aide \u00e0 la d\u00e9cision th\u00e9rapeutique pour que les praticiens puissent personnaliser les traitements, sachant que l\u2019embryon de poulet est un environnement favorable \u00e0 la formation de tumeurs et de m\u00e9tastases en des temps tr\u00e8s rapides (quelques jours seulement).<\/li>\n<li style=\"text-align: justify;\">Contribuer aux programmes de d\u00e9veloppement des th\u00e9rapies cibl\u00e9es, de recherche de biomarqueurs pr\u00e9dictifs et de tests compagnons pour les biotechs et entreprises pharmaceutiques.<\/li>\n<li style=\"text-align: justify;\">D\u00e9velopper ses propres th\u00e9rapies, biomarqueurs, et tests compagnons notamment dans le champ de l\u2019oncop\u00e9diatrie pour lequel il existe des besoins non combl\u00e9s importants.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span style=\"color: #ff6600;\"><strong>Un soutien fort de PULSALYS<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\">La startup cr\u00e9\u00e9e en mars 2016 s\u2019est appuy\u00e9e sur Pulsalys dans un premier temps pour prot\u00e9ger sa technologie par plusieurs brevets, puis pour identifier son futur CEO, Fr\u00e9d\u00e9ric Berget qui a rejoint la soci\u00e9t\u00e9 depuis mai 2017 <em>[<a href=\"https:\/\/www.pulsalys.fr\/success-story-oncofactory-3-questions-a-frederic-berget-ceo-de-societe\/\" target=\"_blank\" rel=\"noopener noreferrer\">Lire aussi l\u2019interview de Fr\u00e9d\u00e9ric Berget<\/a>]<\/em><em>.<\/em> <em>\u00a0<\/em>La responsable de l\u2019\u00e9quipe de recherche Val\u00e9rie Castellani a par ailleurs b\u00e9n\u00e9fici\u00e9 du programme Valoritech qui a permis de structurer la startup en compl\u00e9ment de l\u2019accompagnement par la SATT.<\/p>\n<p style=\"text-align: justify;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-10104 alignright\" src=\"https:\/\/www.pulsalys.fr\/wp-content\/uploads\/2017\/04\/Signature-Oncofactory-Pulsalys-09-03-2018_site-250x165.jpg\" alt=\"\" width=\"291\" height=\"192\" \/>La pleine r\u00e9ussite de ce projet s&#8217;est traduit par la signature, le 9 mars 2018, d&#8217;une licence d&#8217;exploitation entre la startup OncoFactory et la SATT Pulsalys qui conc\u00e8de les droits d&#8217;exploiter la technologie issue de l&#8217;Institut NeuroMyoG\u00e8ne.<\/strong><\/p>\n<p><em>\u00ab\u00a0Gr\u00e2ce \u00e0 sa technologie, Oncofactory va devenir acteur de la cha\u00eene de valeur du drug discovery et de celle de la m\u00e9decine personnalis\u00e9e en oncologie\u00a0\u00bb<\/em> souligne Fr\u00e9d\u00e9ric Berget.<\/p>\n<p style=\"text-align: right;\"><em><span style=\"color: #333399;\">Fr\u00e9d\u00e9ric Berget &amp;\u00a0 Sophie Jullian \u00a9PULSALYS\/NM<\/span><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>\u00a0<\/strong><\/p>\n<table style=\"height: 292px;\" border=\"1\" width=\"645\">\n<tbody>\n<tr style=\"height: 188px;\">\n<td style=\"border-color: #e78700; width: 635px; height: 188px;\">\n<p><span style=\"color: #ff6600;\">\u00a0<strong><u>En bref<\/u><\/strong><\/span><\/p>\n<ul>\n<li><strong>Cr\u00e9ation<\/strong>\u00a0: Mars 2016<\/li>\n<li><strong>Lieu<\/strong> : Lyon 8<sup>\u00e8me<\/sup> (Domaine Rockefeller)<\/li>\n<li><strong>Fondatrices<\/strong> : Val\u00e9rie Castellani-Lincontang, C\u00e9line Delloye-Bourgeois, Thierry Delloye<\/li>\n<li><strong>Nombre de personnes\u00a0<\/strong>: 6 actuellement, 10 \u00e0 l\u2019horizon 2019.<\/li>\n<li><strong>Palmar\u00e8s 2017<\/strong> :\u00a0 Troph\u00e9e <em>R2B<\/em> <em>ONCO<\/em> (D\u00e9c) \/ <strong>2016<\/strong>\u00a0: Laur\u00e9at du Concours Mondial de l\u2019innovation, cat\u00e9gorie Amor\u00e7age \/ <strong>2015<\/strong>\u00a0: Laur\u00e9at du concours<em> I-LAB &#8211;<\/em> Concours national d&#8217;aide \u00e0 la cr\u00e9ation d&#8217;entreprises de technologies innovantes, cat\u00e9gorie <em>Emergence <\/em>(Juil.)<\/li>\n<li><strong>Chiffre d\u2019affaires<\/strong> : NC (1<sup>er<\/sup> CA attendu pour 2018)<\/li>\n<li><strong>Site internet :<\/strong> <a href=\"http:\/\/www.oncofactory.com\/\">www.oncofactory.com<\/a><\/li>\n<li><strong>Contact Oncofactory<\/strong> : <a href=\"mailto:frederic.berget@oncofactory.com\">frederic.berget[@]oncofactory.com<\/a><\/li>\n<li><strong>Contact chef de projet sant\u00e9<\/strong> : <a href=\"Agnes.Savigner@pulsalys.fr\">joseph.andre[@]pulsalys.fr<\/a><\/li>\n<li><strong>Laboratoire impliqu\u00e9<\/strong>\u00a0: <a href=\"https:\/\/www.labex-cortex.com\/fr\/content\/cgphimc-centre-de-genetique-et-de-physiologie-moleculaire-et-cellulaire\">Institut NeuroMyoG\u00e8ne (INMG)<\/a><\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>D\u00e9fi relev\u00e9 par la startup de biotechnologies lyonnaise OncoFactory: cr\u00e9er des r\u00e9pliques miniatures de cancer dans un embryon aviaire afin de tester l\u2019efficacit\u00e9 de drogues anticanc\u00e9reuses. Lire l&#8217;interview de Fr\u00e9d\u00e9ric Berget, CEO de OncoFactory Un projet n\u00e9 au c\u0153ur d\u2019un laboratoire acad\u00e9mique C\u2019est initialement au sein du Centre de G\u00e9n\u00e9tique et de Physiologie Mol\u00e9culaire et [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":9570,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567,568],"tags":[],"class_list":["post-9565","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en","category-successstories-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pulsalys : La th\u00e9ranostique en oncologie, le d\u00e9fi ambitieux de la startup OncoFactory - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Daphn\u00e9 THOMAS\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/\"},\"author\":{\"name\":\"Daphn\u00e9 THOMAS\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/b887fcdc4ba6e2867d3c7d4662a744de\"},\"headline\":\"Pulsalys : La th\u00e9ranostique en oncologie, le d\u00e9fi ambitieux de la startup OncoFactory\",\"datePublished\":\"2018-06-19T09:05:21+00:00\",\"dateModified\":\"2018-06-19T09:42:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/\"},\"wordCount\":856,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/06\/Onco.jpg\",\"articleSection\":[\"News\",\"Success Stories\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/\",\"url\":\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/\",\"name\":\"Pulsalys : La th\u00e9ranostique en oncologie, le d\u00e9fi ambitieux de la startup OncoFactory - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/06\/Onco.jpg\",\"datePublished\":\"2018-06-19T09:05:21+00:00\",\"dateModified\":\"2018-06-19T09:42:44+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/b887fcdc4ba6e2867d3c7d4662a744de\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/06\/Onco.jpg\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/06\/Onco.jpg\",\"width\":2133,\"height\":1190},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pulsalys : La th\u00e9ranostique en oncologie, le d\u00e9fi ambitieux de la startup OncoFactory\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/b887fcdc4ba6e2867d3c7d4662a744de\",\"name\":\"Daphn\u00e9 THOMAS\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/daphne\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pulsalys : La th\u00e9ranostique en oncologie, le d\u00e9fi ambitieux de la startup OncoFactory - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/","twitter_misc":{"Written by":"Daphn\u00e9 THOMAS","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/"},"author":{"name":"Daphn\u00e9 THOMAS","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/b887fcdc4ba6e2867d3c7d4662a744de"},"headline":"Pulsalys : La th\u00e9ranostique en oncologie, le d\u00e9fi ambitieux de la startup OncoFactory","datePublished":"2018-06-19T09:05:21+00:00","dateModified":"2018-06-19T09:42:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/"},"wordCount":856,"image":{"@id":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/06\/Onco.jpg","articleSection":["News","Success Stories"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/","url":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/","name":"Pulsalys : La th\u00e9ranostique en oncologie, le d\u00e9fi ambitieux de la startup OncoFactory - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/06\/Onco.jpg","datePublished":"2018-06-19T09:05:21+00:00","dateModified":"2018-06-19T09:42:44+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/b887fcdc4ba6e2867d3c7d4662a744de"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/06\/Onco.jpg","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2018\/06\/Onco.jpg","width":2133,"height":1190},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/theranostique-oncologie-defi-ambitieux-de-startup-oncofactory\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Pulsalys : La th\u00e9ranostique en oncologie, le d\u00e9fi ambitieux de la startup OncoFactory"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/b887fcdc4ba6e2867d3c7d4662a744de","name":"Daphn\u00e9 THOMAS","url":"https:\/\/www.satt.fr\/en\/author\/daphne\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/9565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=9565"}],"version-history":[{"count":1,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/9565\/revisions"}],"predecessor-version":[{"id":9571,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/9565\/revisions\/9571"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/9570"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=9565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=9565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=9565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}